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Original Article
Introduction
P53, a tumour suppressor gene localized to chromosome
17p13.1, is the most thoroughly characterized gene of human
bladder cancer.1 The gene consists of 11 exons that encodes for
p53, a 393 amino-acid, 53 kDa nuclear protein2–4 that functions
as a transcription factor regulating the expression of many
downstream genes such as p21,5 bax6 and bcl-2.7 This leads to
cell growth arrest, apoptosis or other cellular mechanisms
allowing the cell to adapt to mutational insults.8 The normal
p53 gene and its protein product are important in regulating
cell proliferation. It is called the “gate-keeper gene” because it
arrests the cell cycle at the G1 phase in the event of DNA
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damage, allowing the damage to be repaired and reducing the
probability of a mutation.2,9,10 In neoplastic cells containing
mutant p53 protein, the cells might have an increased resistance
to radiation, chemotherapeutic drugs and enhanced frequency
of other mutational events.2
Various studies report that mutant p53 protein is commonly
detected in bladder carcinomas,11,12 especially in more advanced
cancers. This suggests that the p53 gene has probably mutated
in the later stage of carcinogenesis.13,14 The mutant p53
protein is stable and has a long half-life compared to the
normal protein, with a half-life of 5 to 40 minutes.15–17 This
phenomenon results in the accumulation of the mutant protein
in the nucleus, which renders it detectable by immunohisto-
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OBJECTIVES: To study the incidence of p53 oncoprotein overexpression and its relationship to tumour grade,
stage and clinical prognosis in a cohort of local Malaysian patients.
METHODS: All cases of transitional cell carcinoma (TCC) of the bladder diagnosed and treated at the University
of Malaya Medical Centre from January 1995 to December 2000 were retrieved from the hospital records. Sections
from paraffin-embedded tissues were retrieved and stained for p53 oncoprotein using immunohistochemistry
techniques. P53 oncoprotein results were analyzed in relation to tumour grade, stage and clinical prognosis.
Fisher’s exact test was used to evaluate the relationship between categorical variables and the Kaplan-Meier
procedure was used to assess survival outcomes. The Cox regression model was used for multivariate analysis.
RESULTS: A total of 64 cases were studied. The mean follow-up period was 23.7 months. The number of
p53 positive cases was significantly higher in high-grade (G3) (p = 0.006) and muscle-invasive tumours (≥ T2,
p = 0.035). The status of p53 expression had no significant association with recurrence-free (p = 0.594) or overall
survival (p = 0.955). In multivariate analysis, a multiplicity of tumours at presentation (p = 0.004) and a history of
cigarette smoking (p = 0.016) were independent predictors of recurrence. Tumour stage (p = 0.024) was the single
independent predictor for poor overall survival.
CONCLUSIONS: Overexpression of p53 is associated with TCC of higher grade and tumour stage. It had no
significant impact on prognosis in this cohort of TCC cases. (Asian J Surg 2003;26(1):31–6)
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chemical (IHC) methods.18,19 P53 gene mutations can also be
studied at the genomic level using polymerase chain reaction-
single strand conformation polymorphism (PCR-SSCP)14,20–22
and DNA sequencing.11,20,23 Most of the genetic mutations are
detected in high-grade tumours.11,24,25 Detection of p53
overexpression using IHC is reported to correlate well with p53
mutations, as determined by PCR-SSCP and DNA sequence
analysis.26,27
P53 mutation has been studied for its potential as a
marker for prognosis and survival outcomes,8,19,27 chemosensi-
tivity,10,28 as a predictor of treatment failure after Bacillus
Calmette-Guerin therapy,29,30 cancer detection24,31 and as
a target for gene therapy.32 Recent evidence indicates that the
level of mutant p53 protein in transitional cell carcinoma
(TCC) is important for the management of urinary bladder
cancer, in that advanced stage cancers that overexpress p53
protein may benefit from adjuvant chemotherapy after
cystectomy.20 Nonetheless, the question remains whether or
not p53 overexpression can be used as a predictive marker for
TCC tumour progression, recurrence and prediction of poor
survival.
There are many reports elucidating the relationships
between the loss of p53 protein function and tumour grade,
stage and survival outcomes (recurrence, progression and
overall survival) in TCC.19,20,23,33–36 Nonetheless, no conclusive
evidence has emerged from these studies. Most of these studies
applied immunohistochemical techniques for the detection
of p53 oncoprotein because they are inexpensive, easy to perform
and applicable as a routine laboratory procedure compared
to molecular methods.8,37 The majority of the studies found
that most of the aggressive and advanced stage cancers over-
express p53 protein, and a number of these studies concluded
in favour of p53 overexpression as an independent prognostic
marker.18,19,24,26,27,36,38–40 On the other hand, there are other
studies reporting that p53 overexpression does not predict
recurrence and survival in TCC of the urinary bladder.33,41–45
We analyzed the overexpression of p53 oncoprotein in TCC
of the bladder in a cohort of multiracial Malaysian patients,
with the aim of adding to the pool of knowledge about p53
protein expression and its relationships to tumour stage,
grade and survival outcomes in Asian bladder cancer.
Patients and methods
All cases of first-time diagnosed TCC of the urinary bladder
were retrieved from the medical records of the University of
Malaya Medical Centre (UMMC), from January 1995 to
December 2000, and were included in this study. The
demographic data, clinical management and progress of these
patients were obtained from the patient records.
Formalin-fixed, paraffin-embedded tissues from the
primary tumours were retrieved from the archives of the
Pathology Department at UMMC. The haematoxylin and
eosin slides of the tissue samples were reviewed, independently
graded according to Mostofi et al’s grading scheme46 and
staged according to the T staging system of tumours-nodes-
metastasis (TNM)47 by two pathologists (PSC and MN).
Immunohistochemistry
Mouse monoclonal antibody DO 7 (Dako, A/S, Golstrup,
Denmark) was used as the primary antibody for the detection
of p53 oncoprotein. The immunohistochemical stains were
performed on 4–µm-thick tissue sections, microwaved in citrate
buffer (pH 6.0) at 99°C for 25 minutes to retrieve the antigen.
A secondary goat anti-mouse antibody conjugated with
peroxidase-labelled dextran polymers was used (Dako
Envision™, Carpinteria, CA, USA). Reactivity was visualized by
adding diamino-benzidine (Dako Liquid DAB Substrate-
Chromogen System, Carpinteria, CA, USA). A section of
squamous cell carcinoma of the lung was used as a positive
control for every batch of samples stained.
A tissue sample was considered positive for p53 oncoprotein
overexpression when at least 20% of the tumour cell population
showed positive nuclear reactivity. Samples demonstrating
less than 20% nuclear reactivity were considered as non-
expressors.
Statistical analysis
The correlation of p53 nuclear staining with tumour stage,
grade and other clinical variables was analyzed using Fisher’s
exact test. The Kaplan-Meier procedure was used for univariate
survival analysis. The recurrence-free survival (RFS) was defined
as the time period (in months) from the date of diagnosis to
the date of the first documented clinical recurrence. The
overall survival (OS) was defined as the time period from the
date of diagnosis to the date of death from any cause. The
relationship between the different survival curves was assessed
using the log-rank test. Cases with no follow-up data were
excluded from the analysis. For multivariate analysis, the Cox
regression model was used. All p values reported are two-sided
and values of p < 0.05 are considered as significant. All analyses
were performed using SPSS (Statistical Package for the Social
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Sciences) software (version 10.0)
Results
A total of 64 cases of TCC of the urinary bladder were included
in this study (from January 1995 to December 2000). All of the
cases studied were newly diagnosed and were treated at UMMC,
following the standard treatment protocol for TCC. The
demographic and clinical data are presented in Table 1.
P53 overexpression was present in 42 out of the 64 cases
(66%). The distribution of the proportion of tumours with p53
overexpression according to tumour stage and grade is shown
in Table 2.
There was one case in which the tumour stage could not be
ascertained from the available data and the archival specimen.
A statistically significant relationship was noted between
p53 overexpression and tumours of higher stage (Ta/T1 vs ≥ T2;
Table 1. Characteristics of patients
Number of patients 64
Sex: Male 55 (85.9%)
Female   9 (14.1%)
Age: Mean ± SD 63.7 ± 15.1 yr
Median 64.5 yr
Range 20–90 yr
Ethnic group: Malay 16 (25.0%)
Chinese 41 (64.1%)
Indian   7 (10.9%)
Tumour stage: Ta 28 (43.8%)
T1 18 (28.1%)
T2 6 (9.4%)
> T2 11 (17.4%)
Data unavailable 1
Tumour grade: Grade 1 16 (25.0%)
Grade 2 24 (37.5%)
Grade 3 24 (37.5%)
Follow-up: Mean ± SD 23.7 ± 21.0 months
Median 14.0 months
SD = standard deviation.
Table 2. p53 overexpression according to tumour stage and grade
P53 positive/total cases (%)
Tumour stage: Ta 13/28 (46.4)
T1 13/18 (72.2)
≥ T2 15/17 (88.2)
Tumour grade: Grade 1 9/16 (56.3)
Grade 2 12/24 (50.0)
Grade 3 21/24 (87.5)
p = 0.035). A similar trend was also observed for tumour grade,
in which tumours of higher grade were associated with a
higher incidence of p53 overexpression (grades 1/2 vs grade 3;
p = 0.006). The overexpression of p53 did not appear to be
associated with age at presentation (p = 0.220), patient gender
(p = 1.000), ethnic group (p = 0.405), history of cigarette
smoking (p = 0.570) or multiplicity of tumours at presentation
(p = 1.000).
For the study of survival pattern, complete data of 53
patients were available for analysis. The mean follow-up was
23.7 months (standard deviation, 20.9 months; median, 14.0
months). RFS did not differ between the p53 overexpression
and non-expression groups (p = 0.594) (Figure 1). The mean
duration to recurrence was 35.4 months (95% confidence
interval, CI, 23.7–47.0) for tumours that overexpressed p53
and 35.5 months (95% CI, 24.6–46.4) for tumours that did not.
In a multivariate analysis of RFS taking into consideration age
at presentation, p53 positivity, tumour stage, grade, multiplicity
of tumours at presentation and history of cigarette smoking,
were independent predictors of recurrence (p = 0.004 and 0.
016, respectively).
Univariate analysis for overall survival revealed that p53
overexpression was not significantly associated with a decreased
probability of survival (p = 0.955) (Figure 2). The mean time to
death was 52.5 months (95% CI, 42.0–63.0) for tumours that
overexpressed p53 and 52.8 months (95% CI, 39.7–65.9) for
tumours that did not overexpress p53 . Multivariate analysis
considering age at presentation, p53 positivity, and tumour
stage and grade showed that high tumour stage was
the independent predictor for unfavourable overall survival
(p = 0.024). Further analysis showed no significant difference
in RFS between tumours with or without p53 overexpression
for Ta and T1 tumours (p = 0.355) (Figure 3).
Discussion
TCC is a common form of urinary bladder cancer. Its treatment
demands a substantial amount of resources due to its
propensity to recur after primary treatment of transurethral
resection. Long-term follow-up is an essential component of
the management plan. Many predictive and prognostic factors
have been studied and evaluated for their usefulness in
predicting clinical progression and outcome for this cancer,
with the aim of identifying the subgroup of patients who
would require more aggressive primary or adjuvant treatment
and closer, more vigilant, follow-up. This is especially true in
superficial, non-muscle invasive cancers, as tumours of similar
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grade might behave very differently. In the extensive search for
additional prognostic factors, p53 has emerged as one of the
most promising candidates to fulfil the role. As far as we know,
this study represents the first in-depth analysis of p53
overexpression in TCC of the urinary bladder in a multiracial
Malaysian population.
The overexpression of p53 protein was noted in 66% of the
cases studied. The incidence of p53 positivity in non-muscle
invasive (Ta/T1) and invasive (≥ T2) tumours was 56% and
88%, respectively. Tumours of all stages in this cohort
demonstrated a high incidence of p53 positivity compared to
that of other studies, despite a relatively high cut-off point of
20% for the evaluation of p53 overexpression. In general, the
incidence of p53 positivity for non-muscle invasive and invasive
tumours ranged from 15% to 50% for non-muscle invasive
tumours and from 50% to 85% for invasive tumours in other
reports.8,21,23,34–36,39 The biological and clinical significance of
this finding is uncertain. It might imply that tumours in our
series of cases were more aggressive in nature and, hence,
would be an interesting aspect for future studies.
Tumours of higher stage and grade demonstrated higher
incidence of p53 positivity in our study. This finding is in
accordance with most other studies to date.11,24,25 It supports
the hypothesis that p53 mutation and subsequent production
of mutant p53 protein probably occurs at a later stage in the
process of TCC carcinogenesis of the bladder.13,14 As a “gate-
keeper” gene, the loss of p53 function gives the tumour a
survival advantage, as the normal cell-regulatory functions of
G1 arrest and the initiation of apoptosis are lost in face of
carcinogenic insults. Furthermore, there is evidence that
normal p53 has an anti-angiogenic function.48 Thus, in the
case of p53 mutation, the angiogenesis inhibition function
would be lost and potential for better growth and distant
metastasis might be enhanced through angiogenesis.
Analysis of the results showed that p53 overexpression was
not related to clinical variables such as age at presentation,
patient sex, ethnic group, history of smoking or multiplicity of
tumours at presentation. It is worthy to note that previous
studies also found no difference in the incidence of p53 over-
expression between smokers and non-smokers. Nonetheless,
the p53 mutation spectrum is different between smokers
and non-smokers.49,50 The three main ethnic groups (Malay,
Chinese, Indian) in this study appeared to be no different in
terms of the incidence of p53 overexpression. The relatively
small number of patients, especially ethnic Indians, made
further meaningful analysis of patient subgroups according
to tumour stage impractical.
Figure 1. Kaplan-Meier survival curves for recurrence-free survival
according to p53 status.
bability of remaining recurrence-free
Figure 3. Kaplan-Meier survival curves for recurrence-free survival
according to p53 status (for superficial, Ta and T1 tumours).
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Figure 2. Kaplan-Meier survival curves for overall survival according
to p53 status.
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The aim of defining the role of p53 overexpression as
a prognostic factor in TCC of the bladder remains to be
ascertained. In this study, no significant relationship was
found between p53 overexpression and RFS or OS when
cases of all stages were analyzed. For the clinically important
subgroup of superficial, non-muscle invasive cases, analysis
showed that RFS was independent of the p53 status of the
primary tumours. Thus, p53 status does not appear to predict
which superficial tumours would be more likely to recur.
Controversy still prevails on the role of p53 as a marker
for bladder cancer progression. Our findings concur with
many others that failed to show the benefit of p53 IHC
studies,33,41,44,45 which contradicts the reports that demon-
strated a positive correlation between p53 positivity and
a higher risk of tumour recurrence and a poorer survi-
val.18,19,24,26,27,36,38–40
There is little doubt that IHC can identify most cases in
which the cells had mutated p53 genes, thus, providing a
reliable method to study p53 abnormalities in various cancers.
However, 15% to 20% of tumours with p53 gene mutation fail
to show overexpression by IHC studies.26,27 Furthermore, some
tumours with nuclear expression of p53 lacked evidence of
p53 gene mutation. The common problems faced in the
interpretations of the various IHC studies of p53 in bladder
cancer are the use of different antibodies, different cut-off
points for determination of overexpression, case selection
method and length of follow-up. Hence, in this study, we used
DO-7, which is a well-established antibody for p53 in IHC, and
the 20% cut-off point was chosen based on previous studies
that suggested that more than 20% staining of tumour cell
nuclei for p53 was an independent predictor of tumour
progression.13,51 Moreover, the number of patients available
for analysis was certainly compatible with other studies of
similar nature.
In summary, this study on TCC of the bladder in Malaysian
patients demonstrated a high incidence of p53 oncoprotein
overexpression. While p53 overexpression was associated with
tumours of higher tumour stage and grade, this study failed to
support the useful role of p53 overexpression for predicting
disease progression. Since there is a lack of clear consensus or
definite treatment protocol regarding the use of p53 as a
prognostic factor, traditional prognostic variables such as
tumour stage remain the main factors to be considered in the
management of bladder cancer. Refining and standardizing
current research methodologies and international collabora-
tion to enrol larger numbers of patients would certainly help
to resolve the current impasse.
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